Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small molecule discovered by a Chinese biotech that has built a business around botanical drugs.

Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, Sanofi has returned with 300 million euros ($326 million) to set up a more permanent radioligand project.

Ceribell rang in a $180.3 million IPO last week, with its public debut on the Nasdaq coming in well above its first pricing goal of about $101 million and its stock price trading up about 47% following the launch.

Cell therapy biotech Tolerance Bio has unveiled with $17.2 million and a mission of targeting immune diseases by stretching and saving the function of a key organ.

Ocean Biomedical has signed a $32 million biobucks deal with a Polish biotech to secure the rights to a batch of preclinical YKL-40 inhibitors that it hopes have potential against cancers, plus inflammatory and fibrotic diseases.

Forbion has unveiled its largest haul to date, as the European life-sciences-focused VC firm brings in more than 2 billion euros across two funds.

After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is scooping up the biotech for $2.5 billion.

CMR Surgical obtained a de novo clearance from the FDA for its Versius surgical system, finally allowing its modular, cart-based, laparoscopic robot to come to U.S. shores.

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), Gilead has decided to walk away from a $785 million biobucks deal in the tricky liver disease.

Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest biotechs to list on the Nasdaq.